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The mammalian target of rapamycin complex 1
(mTORC1) regulates activation of immune cells
and cellular energy metabolism. Although glycol-
ysis has been linked to immune functions, the
mechanisms by which glycolysis regulates NLRP3
inflammasome activation remain unclear. Here,
we demonstrate that mTORC1-induced glycolysis
provides an essential mechanism for NLRP3 in-
flammasome activation. Moreover, we demonstrate
that hexokinase 1 (HK1)-dependent glycolysis, un-
der the regulation of mTORC1, represents a critical
metabolic pathway for NLRP3 inflammasome acti-
vation. Downregulation of glycolysis by inhibition
of Raptor/mTORC1 or HK1 suppressed both pro-
IL-1bmaturation and caspase-1 activation in macro-
phages in response to LPS and ATP. These results
suggest that upregulation of HK1-dependent glycol-
ysis by mTORC1 regulates NLRP3 inflammasome
activation.INTRODUCTION
Inflammasomes are multi-protein complexes that activate cas-
pase-1 and downstream immune responses, including the
maturation and secretion of pro-inflammatory cytokines (e.g.,
IL-1b and IL-18) (Franchi et al., 2009; Schroder and Tschopp,
2010; Sutterwala et al., 2006). The cytoplasmic nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs)
constitute critical components of the inflammasome. NLRs
interact with the adaptor apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC), which
recruits pro-caspase-1 (Latz et al., 2013). Among the known
NLR-containing inflammasomes, the NOD-, leucine-rich re-
gion-, and pyrin domain-containing 3 (NLRP3) inflammasome
(also known as cryopirin or NALP3) responds to activation by
a wide range of endogenous and exogenous agonists (Franchi
et al., 2009; Schroder and Tschopp, 2010), and has been
implicated in the pathogenesis of several diseases, including102 Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authorscancer, infectious diseases, and autoimmune diseases (Bru-
chard et al., 2013; Franchi et al., 2009; Schroder and Tschopp,
2010).
The mammalian target of rapamycin complex 1 (mTORC1)
promotes activation of NK and Treg cells (Marc¸ais et al., 2014;
Yang et al., 2013; Zeng et al., 2013), and acts as a crucial regu-
lator of cellular energy metabolism (Cairns et al., 2011; Laplante
and Sabatini, 2012). The mTORC1 is associated with activation
of cellular glycolysis, which involves the increased translation
of glycolytic enzymes or their transcriptional regulators (Du¨vel
et al., 2010; Elstrom et al., 2004). Moreover, mTORC1 regulates
translation and ribosome biogenesis through the phosphoryla-
tion of the translational regulators eukaryotic translation initiation
factor 4E (eIF4E)-binding protein 1 (4E-BP1) and S6 kinase 1
(S6K1) (Laplante and Sabatini, 2012; Ma and Blenis, 2009;
Richter and Sonenberg, 2005). The phosphorylation of 4E-BP1
prevents its binding to the cap-binding protein eIF4E, enabling
it to engage in the eIF4F complex that is required for the initiation
of cap-dependent translation (Laplante and Sabatini, 2012; Ma
and Blenis, 2009; Richter and Sonenberg, 2005). The activation
of S6K1, through multiple effectors, leads to increased mRNA
biogenesis as well as translational initiation and elongation
(Laplante and Sabatini, 2012; Ma and Blenis, 2009; Richter and
Sonenberg, 2005).
Glycolysis is a critical pathway in cellular glucose metabolism
that provides intermediates for energy generation (DeBerardinis
et al., 2008a, 2008b; Koppenol and Bounds, 2009; Vander Hei-
den et al., 2009). The phosphorylation of glucose by hexokinase
represents the rate-limiting step in the regulation of glycolysis
(Bustamante et al., 1981; Cairns et al., 2011). HKs play a vital
role in the cellular uptake and utilization of glucose (Arora
et al., 1990; Baijal and Wilson, 1995; Greiner et al., 1994). In
mammals, four HK isozymes (HK1–4) have been identified,
each with distinct subcellular localization, kinetics, substrate
specificities, and physiological functions (Azoulay-Zohar and
Aflalo, 1999, 2000; Baijal and Wilson, 1995; Crane and Sols,
1953; Mathupala et al., 2009; Parry and Pedersen, 1984; Wilson,
2003).
Recent studies suggested that glycolysis is involved in
immune responses (Krawczyk et al., 2010; Masters et al.,
2010; Tannahill et al., 2013; Zhou et al., 2010). The induction
of glycolysis by Toll-like receptor (TLR) agonists facilitates the
Figure 1. Inhibition of mTORC1 Suppresses
NLRP3 Inflammasome Activation In Vitro
and In Vivo
(A) ELISA assay shows IL-1b secretion in super-
natants from wild-type peritoneal macrophages
pre-treated with Torin1 (250 nM) for 1 hr before
ATP (5 mM), nigericin (6.7 mM), silica (200 ng/ml),
MDP (200 ng/ml), or flagellin (200 ng/ml) treatment,
after LPS (500 ng/ml, 4 hr) stimulation. *p < 0.05 by
ANOVA.
(B) ELISA assay shows IL-1b secretion in super-
natants from wild-type peritoneal macrophages
pre-treated with Torin1 (0, 60 125, 250, 500, or
1,000 nM) for 1 hr before ATP (5 mM, 30 min) after
LPS (500 ng/ml, 4 hr) stimulation (representative of
three independent experiments). *p < 0.05 by
ANOVA.
(C) Immunoblot analysis for caspase-1, NLRP3,
and ASC of cell lysates from wild-type BMDMs
pre-treated with Torin1 (250 nM) for 1 hr
before ATP (2 mM, 30 min) treatment, after LPS
(500 ng/ml, 4 hr) stimulation. b-actin served as the
standard.
(D) Immunoblot analysis for caspase-1, NLRP3,
and ASC of cell lysates from wild-type BMDMs
pre-treated with rapamycin (10 nM) for 1 hr before
ATP treatment after LPS stimulation. b-actin
served as the standard.
(E) ELISA assays show IL-1b, IL-18, and TNF se-
cretions in supernatants from wild-type BMDMs
pre-treated with Torin1 (250 nM) for 1 hr before
ATP treatment, after LPS stimulation. **p < 0.01 by
ANOVA.
(F) ELISA assays show IL-1b, IL-18, and TNF se-
cretions in serum of wild-type mice after intraper-
itoneal injection of Torin (5 mg/kg) or DMSO for
14 hr, then LPS (10mg/kg) or PBS for 8 hr (PBS, n =
6; LPS, n = 8). *p < 0.05 by ANOVA.maturation and activation of dendritic cells (Everts et al., 2014;
Krawczyk et al., 2010). High concentrations of glucose increase
IL-1b secretion through an NLRP3-dependent mechanism
(Zhou et al., 2010). The inhibition of glycolysis in macrophages
suppressed IL-1b gene expression in response to lipopolysac-
charide (LPS) treatment (Masters et al., 2010; Tannahill et al.,
2013). The NLRP3 inflammasome has been implicated in the
pathogenesis of metabolic disorders such as non-alcoholic
fatty liver disease, obesity, and diabetes (Henao-Mejia et al.,
2012; Jourdan et al., 2013; Vandanmagsar et al., 2011). How-
ever, the mechanisms by which glycolysis regulates NLRP3 in-
flammasome activation remain unclear.
In this paper, we demonstrate that genetic and pharmaco-
logic inhibition of mTORC1 suppressed HK1-dependent glycol-
ysis, caspase-1 activation, and the maturation and secretions
of IL-1b and IL-18 in vitro and in vivo, under pro-inflamma-
tory conditions. Furthermore, genetic and pharmacologic inhi-Cell Reports 12, 102bition of HK1 suppressed caspase-1
activation and secretions of IL-1b and
IL-18 in macrophages. Our results, taken
together, suggest that mTORC1-induced
HK1-dependent glycolysis provides anessential metabolic mechanism for NLRP3 inflammasome
activation.
RESULTS
Inhibition of mTORC1 Suppressed NLRP3
Inflammasome Activation In Vitro and In Vivo
To investigate the function of mTORC1 in inflammasome
activation, we inhibited mTORC activity in LPS-primed primary
peritoneal macrophages using Torin1, a competitive mTORC1/2
inhibitor (Thoreen et al., 2009). We analyzed the secretion of
IL-1b in LPS-primed macrophages that were treated with Torin1
for 1 hr before treatment with specific NLRP3 inflammasome
activators, including ATP, nigericin, and silica. Torin1 sup-
pressed IL-1b secretion in macrophages in response to
treatment with NLRP3 inflammasome activators (Figure 1A).
In contrast, Torin1 had no effect on the activation of IL-1b–115, July 7, 2015 ª2015 The Authors 103
secretion in response to treatment with muramyldipeptide
(MDP), an NLRP1 inflammasome activator, or flagellin, an
NLR family CARD domain-containing protein 4 (NLRC4) inflam-
masome activator (Figure 1A). Consistently, pre-treatment
with Torin1 dose-dependently suppressed IL-1b secretion in
response to ATP treatment in LPS-primed macrophages (Fig-
ure 1B). These results suggest that mTORC1/2 is involved in
NLRP3 inflammasome activation in response to NLRP3 inflam-
masome activators.
Next, we analyzed caspase-1 activation in LPS-primed
primary bone-marrow-derived macrophages (BMDMs) pre-
treated with Torin1 for 1 hr before ATP treatment. Torin1 sup-
pressed caspase-1 activation in wild-type BMDMs in response
to LPS and ATP, compared to vehicle control, while NLRP3
and ASC expressions were unchanged (Figure 1C). Similarly,
rapamycin, a selective mTORC1 inhibitor (Benjamin et al.,
2011), suppressed caspase-1 activation in wild-type BMDMs
in response to LPS and ATP, compared to vehicle control (Fig-
ure 1D). Moreover, the secretions of IL-1b and IL-18 were in-
hibited by Torin1 in wild-type BMDMs, while tumor necrosis
factor (TNF) was unchanged (Figure 1E). Furthermore, Torin1
suppressed serum levels of IL-1b and IL-18 in response to
LPS challenge in vivo, whereas TNF was unchanged (Fig-
ure 1F). These results suggest that the inhibition of mTORC1
suppressed NLRP3 inflammasome activation in vitro and
in vivo.
mTORC1-Dependent Glycolysis Is a Critical Metabolic
Pathway for NLRP3 Inflammasome Activation
Given that mTORC1 is associated with the activation of cellular
glycolysis (Du¨vel et al., 2010; Laplante and Sabatini, 2012;
Rowe et al., 2013), we investigated whether mTORC1-depen-
dent glycolysis can regulate NLRP3 inflammasome activation.
To analyze mTORC1-induced glycolysis during NLRP3 inflam-
masome activation, we measured the extracellular acidification
rate (ECAR), as a measure of lactate production (a surrogate
for the glycolytic rate), and the mitochondrial oxygen consump-
tion rate (OCR) in wild-type peritoneal macrophages pre-treated
with Torin1 for 1 hr before LPS and ATP stimulation. The ECAR
was significantly increased by LPS and ATP stimulation
compared to LPS alone or control treatments (Figure 2A). Impor-
tantly, Torin1 suppressed the induction of ECAR by LPS and ATP
relative to vehicle control (Figure 2A). In contrast, the OCR
measured after LPS and ATP treatment was not changed by
Torin1 treatment compared to vehicle control (Figure 2B).
To confirm that the observed changes in ECAR correspond
to glycolytic flux, we measured the levels of glycolytic metabo-
lites in LPS-primed BMDMs pre-treated with Torin1 for 1 hr
before ATP treatment. Glycolytic metabolites (i.e., phospho-
enolpyruvate [PEP] and citrate) were induced 2-fold by LPS
relative to control (Figure 2C). Interestingly, glycolytic metabo-
lites (i.e., PEP, citrate, and lactate) were also significantly
increased in BMDMs by LPS and ATP, relative to LPS treat-
ment alone or untreated control macrophages (Figure 2C).
Importantly, Torin1 inhibited the activation of glycolysis, as indi-
cated by the suppression of glycolytic metabolite production, in
BMDMs in response to LPS and ATP, relative to vehicle control
(Figure 2C). Similarly, rapamycin suppressed the activation of104 Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authorsglycolytic metabolite (i.e., PEP, citrate, and lactate) production
in response to LPS and ATP relative to vehicle control (Fig-
ure 2D). These results suggest that mTORC1-dependent
glycolysis is a crucial metabolic pathway involved in NLRP3 in-
flammasome activation.
Inhibition of mTORC1 Suppressed the Increase in HK1
Expression during NLRP3 Inflammasome Activation
We investigated the underlying molecular mechanism by which
mTORC1 regulates the high glycolytic phenotype observed
during NLRP3 inflammasome activation. Given that mTORC1
regulates the translation of glycolytic enzymes and their
transcriptional regulators (Du¨vel et al., 2010; Levine and Pu-
zio-Kuter, 2010; Ma and Blenis, 2009), we first examined the
regulation of glycolytic enzymes during NLRP3 inflammasome
activation. We analyzed the protein expression of HK1, the first
key enzyme in the glycolysis pathway, in mitochondrial and
cytosolic protein lysates of BMDMs treated with LPS and
ATP. HK1 was preferentially expressed in mitochondria of
BMDMs (Figure S1A), consistent with previous reports that
HK1 is primarily expressed in mitochondria (Azoulay-Zohar
and Aflalo, 1999; Wilson, 2003). Importantly, the protein
expression of HK1 was markedly increased in response to
LPS and ATP, relative to LPS treatment alone or untreated
control macrophages (Figure S1A). In contrast, we found that
HK2, another major isoform of HK, was not expressed in
BMDMs (Figures S1B and S1C).
Importantly, the inhibition of mTORC1 by Torin1 or rapamycin
suppressed HK1 protein expression in BMDMs in response to
LPS and ATP, compared to vehicle control (Figures 2E and 2F).
In contrast, treatment with Torin1 or rapamycin had no effect
on the activation of 50-AMP-activated protein kinase (AMPK),
which suggested that AMPK was not involved in mTORC1-
dependent glycolysis (Figures 2E and 2F).
HK1 exhibits a higher affinity for the voltage-dependent anion
channel (VDAC)1 isoform than for other mammalian VDAC
isoforms (Azoulay-Zohar and Aflalo, 1999, 2000). Given that
VDAC is essential for NLRP3 inflammasome activation (Zhou
et al., 2011), we investigated whether HK1 interacts with
VDAC1 in the mitochondria, which may provide specific func-
tional advantages for NLRP3 inflammasome activation. We
observed that an interaction between HK1 and VDAC1, as as-
sessed by co-immunoprecipitation (coIP), occurred inmitochon-
dria of mouse J774A.1 macrophages and increased in response
to LPS and ATP (Figure S2A). However, the inhibition ofmTORC1
by Torin1 did not change the interaction between HK1 and
VDAC1 (Figure S2B). These results, taken together, suggest
that the induction of HK1 protein expression is responsible for
the high glycolytic phenotype observed during NLRP3 inflamma-
some activation.
HK1 Is Regulated by NLRP3 Inflammasome Activation
To determine whether HK1-dependent glycolysis is regulated by
activators of other inflammasomes, we examined HK1 expres-
sion in BMDMs in response to activators of the absent in
melanoma 2 (AIM2) inflammasome relative to activators of the
NLRP3 inflammasome pathway. In LPS-primed BMDMs, the
protein expression of HK1 was increased by ATP treatment
Figure 2. mTORC1-Dependent Glycolysis Is a Critical Metabolic Pathway in NLRP3 Inflammasome Activation
(A) ECAR was measured in wild-type peritoneal macrophages pre-treated with Torin1 (250 nM) for 1 hr before ATP (5 mM, 30 min) after LPS (500 ng/ml, 4 hr)
stimulation. Data are mean ± SD.
(B) OCR was measured in wild-type peritoneal macrophages pre-treated with Torin1 (250 nM) for 1 hr before ATP (5 mM, 30 min) after LPS (500 ng/ml, 4 hr)
stimulation. Data are mean ± SD.
(C) PEP, citrate, and lactate production assays from wild-type BMDMs pre-treated with Torin1 (250 nM) for 1 hr before ATP treatment after LPS stimulation
are shown. *p < 0.05 by ANOVA.
(D) PEP, citrate, and lactate production assays fromwild-type BMDMs pre-treated with rapamycin (10 nM) for 1 hr before ATP treatment after LPS stimulation are
shown. *p < 0.05 by ANOVA.
(E) Immunoblot analysis for HK1 and phosphorylation of AMPK of cell lysates from wild-type BMDMs pre-treated with Torin1 (250 nM) for 1 hr before ATP after
LPS stimulation. Total AMPK served as the standard.
(F) Immunoblot analysis for HK1 and phosphorylation of AMPK of cell lysates from wild-type BMDMs pre-treated with rapamycin (10 nM) for 1 hr before ATP
after LPS stimulation. Total AMPK served as the standard.
See also Figures S1 and S2.(Figure S3A). Consistently, caspase-1 activation and secretion of
IL-1b were increased by ATP treatment, whereas TNF was
unchanged (Figure S3B). In contrast, the protein expression of
HK1 was not induced in LPS-primed BMDMs after treatment
with poly(dA:dT), an AIM2 inflammasome activator, comparedto NLRP3 inflammasome activation (Figure S3A). In contrast,
caspase-1 activation and secretion of IL-1b were significantly
increased by poly(dA:dT) in LPS-primed BMDMs (Figures S3A
and S3B). These results suggest specificity of HK1 regulation
during inflammasome activation.Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authors 105
Figure 3. Deficiency of Raptor/mTORC1 Suppresses Caspase-1 Activation, HK1 Expression, and Glycolysis during NLRP3 Inflammasome
Activation
(A) Immunoblot analysis for Raptor, HK1, caspase-1, and IL-1b in cell lysates fromwild-typemouse peritonealmacrophages transducedwith lentiviruses expressing
non-target shRNA (control shRNA) or two independent shRNAs for Raptor (shRaptor 1 and 2) and stimulated with LPS and ATP. b-actin served as the standard.
(B) ELISA assays show IL-1b, IL-18, and TNF secretions from (A). **p < 0.01 by ANOVA.
(C) ECAR was measured in wild-type peritoneal macrophages transduced with lentiviruses expressing non-target shRNA (control shRNA) or shRNA for Raptor
(shRaptor) and stimulated with LPS and ATP. Data are mean ± SD.
(D) OCR was measured in wild-type peritoneal macrophages transduced with lentiviruses expressing non-target shRNA (control shRNA) or shRNA for Raptor
(shRaptor) and stimulated with LPS and ATP. Data are mean ± SD.
(E) Glucose-6-phosphate, citrate, and lactate production assays from wild-type peritoneal macrophages transduced with lentiviruses expressing non-target
shRNA (control shRNA) or two independent shRNAs for Raptor (shRaptor 1 and 2) and stimulated with LPS and ATP are shown. *p < 0.05 by ANOVA.
See also Figure S3.Raptor/mTORC1 Regulates Caspase-1 Activation and
HK1Expression duringNLRP3 InflammasomeActivation
Next, we examined the specificity ofmTORC1 in the regulation of
caspase-1 activation and the protein expression of HK1 during
NLRP3 inflammasome activation. We analyzed whether genetic
deficiency of Raptor, a regulatory-associated protein of the
mTORC1 complex (Kim et al., 2002), could suppress caspase-1
activation and the protein expression of HK1 in macrophages.106 Cell Reports 12, 102–115, July 7, 2015 ª2015 The AuthorsWe used two independent small hairpin RNA (shRNA) lentiviral
constructs against mouse Raptor to deplete Raptor in wild-
type peritoneal macrophages. The activation of caspase-1 and
HK1 protein expression in response to LPS and ATP stimulation
were suppressed by Raptor shRNA transduction relative to con-
trol shRNA transduction, while NLRP3 and ASCwere unchanged
(Figure 3A). Moreover, the secretions of IL-1b and IL-18 were in-
hibited by Raptor shRNA in wild-type peritoneal macrophages,
Figure 4. Deficiency of Rictor/mTORC2 Does Not Suppress Caspase-1 Activation and HK1 Expression during NLRP3 Inflammasome
Activation
(A) Immunoblot analysis for Rictor, HK1, caspase-1, and IL-1b in cell lysates fromwild-typemice peritoneal macrophages transducedwith lentiviruses expressing
non-target shRNA (control shRNA) or two independent shRNAs for Rictor (shRictor 1 and 2) and stimulated with LPS and ATP. b-actin served as the standard.
(B) ELISA assays show IL-1b, IL-18, and TNF secretions from (A).
(C) Glucose-6-phosphate, citrate, and lactate production assays from wild-type peritoneal macrophages transduced with lentiviruses expressing non-target
shRNA (control shRNA) or two independent shRNAs for Rictor (shRictor 1 and 2) and stimulated with LPS and ATP are shown.while TNF was unchanged (Figure 3B). Consistently, knockdown
of mTOR by small interfering RNA (siRNA) inhibited the activation
of caspase-1 and the secretions of IL-1b and IL-18 in mouse
J774A.1 macrophages, relative to control siRNA-transfected
cells (Figures S3C and S3D).
Consistent with the downregulation of HK1 protein expres-
sion, Raptor knockdown by transduction with Raptor shRNA
suppressed the induction of ECAR in macrophages in response
to LPS and ATP, relative to control shRNA transduction
(Figure 3C). In contrast, the OCR measured after LPS and ATP
treatment was not changed by Raptor knockdown in macro-
phages transduced with Raptor shRNA compared to control
shRNA (Figure 3D). The production of glycolytic metabolites
(i.e., glucose-6-phosphate, citrate, and lactate) in response to
LPS and ATP was suppressed in wild-type peritoneal macro-
phages transduced with Raptor shRNA compared to control
shRNA (Figure 3E).
To determine whether caspase-1 activation and the protein
expression of HK1 are regulated by mTORC2 during NLRP3
inflammasome activation, we examined caspase-1 activation
and HK1 expression in response to the depletion of Rictor, a reg-
ulatory-associated protein of the mTORC2 complex (Sarbassov
et al., 2004), in macrophages. We used two independent shRNA
lentiviral constructs against mouse Rictor to deplete Rictor in
wild-type peritoneal macrophages. In contrast to Raptor knock-down, the activation of caspase-1 and HK1 protein expression in
response to LPS and ATP stimulation were not suppressed by
Rictor shRNA transduction relative to control shRNA transduc-
tion (Figure 4A). Similarly, the secretions of IL-1b, IL-18, and
TNF were not inhibited by Rictor knockdown in wild-type perito-
neal macrophages (Figure 4B). Also, the production of glycolytic
metabolites was not changed by Rictor knockdown in wild-type
peritoneal macrophages in response to LPS and ATP compared
to control shRNA-transduced cells (Figure 4C). These results
suggest that Raptor/mTORC1 regulates caspase-1 activation
and HK1 expression during NLRP3 inflammasome activation.
HK1 Expression Is Related to mTORC1-Dependent
Translational Regulation during NLRP3 Inflammasome
Activation
Next, we investigated the molecular mechanism by which
mTORC1 regulates the protein expression of HK1 during
NLRP3 inflammasome activation. Importantly, the inhibition of
mTORC1 by Torin1 suppressed HK1 protein expression in
response to LPS and ATP, compared to vehicle control (Fig-
ure 2D), while HK1 mRNA levels were unchanged (Figure 5A).
Consistent with the downregulation of HK1 protein expression,
Torin1 and rapamycin suppressed translation by inhibiting the
phosphorylation of eIF4E and ribosomal protein S6, which are in-
tegrated into two key translational processes (Ma and Blenis,Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authors 107
Figure 5. mTORC1 Regulates HK1 Expression during NLRP3 Inflammasome Activation
(A) The qPCR analysis for Hk1 gene expression from wild-type BMDMs pre-treated with Torin1 (250 nM) for 1 hr before ATP treatment after LPS stimulation
is shown.
(B) Immunoblot analysis for phosphorylation of eIF4E and S6 of cell lysates fromwild-type BMDMs pre-treated with Torin1 (250 nM) for 1 hr before ATP treatment
after LPS stimulation is shown.
(C) Immunoblot analysis for phosphorylation of eIF4E and S6 of cell lysates from wild-type BMDMs pre-treated with rapamycin (10 nM) for 1 hr before ATP
treatment after LPS stimulation is shown.
(D) Immunoblot analysis for 4E-BP1, HK1, caspase-1, and IL-1b in cell lysates from wild-type mice peritoneal macrophages transduced with lentiviruses
expressing non-target shRNA (control shRNA) or two independent shRNAs for 4E-BP1 (sh4E-BP1 1 and 2) and stimulated with LPS and ATP. b-actin served as
the standard.
(E) ELISA assays show IL-1b, IL-18, and TNF secretions from (D). *p < 0.05 by ANOVA.
See also Figure S3.2009; Richter and Sonenberg, 2005): (1) the cap-dependent
translation by eIF4E, and (2) translation by ribosomal protein
S6 kinase (p70S6K) (Figures 5B and 5C). The translational inhib-
itory protein 4E-BP1 plays a major role in translation by inhibiting
cap-dependent translation initiation through the regulation of
eIF4E phosphorylation by reversible interaction (Richter and So-
nenberg, 2005).
We therefore examined the effect of translation activation by
4E-BP1 knockdown using two independent shRNA lentiviral
constructs against mouse 4E-BP1 on HK1 protein expression
and caspase-1 activation in wild-type peritoneal macrophages.
Importantly, the expression of 4E-BP1 was diminished in
response to LPS and ATP, with a corresponding increase in
HK1 expression, in control shRNA-transduced macrophages
(Figure 5D). Translation activation by 4E-BP1 knockdown using
4E-BP1 shRNA increased the expression of HK1 and caspase-1
activation in response to LPS and ATP in wild-type peritoneal
macrophages, relative to control shRNA transduction (Fig-
ure 5D). Moreover, 4E-BP1 knockdown by 4E-BP1 shRNA
increased the secretions of IL-1b and IL-18 in response to LPS108 Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authorsand ATP in wild-type peritoneal macrophages compared to
control shRNA, whereas TNF was unchanged (Figure 5E). Simi-
larly, 4E-BP1 knockdown by 4E-BP1 siRNA increased the
expression of HK1 and caspase-1 activation in response to
LPS and ATP in mouse J774A.1 macrophages, compared to
control siRNA transfection (Figure S3E). Moreover, 4E-BP1
knockdown increased the secretions of IL-1b and IL-18 in
response to LPS and ATP in mouse J774A.1 macrophages in
comparison to control, while TNF was unchanged (Figure S3F).
These results suggest that the elevation of HK1 protein expres-
sion during NLRP3 inflammasome activation is related to
mTORC1-dependent translational regulation.
mTORC1-Dependent Glycolysis Is a Critical Metabolic
Pathway for NLRP3 Inflammasome Activation
To examine the role of glycolysis activation in NLRP3 inflamma-
some activation, we inhibited glycolysis in macrophages using
2-deoxyglucose (2DG), a potent glycolysis inhibitor (Pelicano
et al., 2006). To determine the inhibitory effect of 2DG on glycol-
ysis in macrophages, wemeasured ECAR in wild-type peritoneal
Figure 6. HK1-Dependent Glycolysis Is Required for NLRP3 Inflammasome Activation
(A) ECAR was measured in wild-type peritoneal macrophages pre-treated with 2DG (0.5 mM) for 2 hr before ATP (5 mM, 30 min) after LPS (500 ng/ml, 4h)
stimulation. Data are mean ± SD.
(B) Immunoblot analysis for caspase-1, NLRP3, ASC, and IL-1b of cell lysates fromwild-type BMDMspre-treatedwith 2DG (0.5mM) for 2 hr before ATP (2mM) for
30 min after LPS stimulation. b-actin served as the standard.
(C) ELISA assays show IL-1b, IL-18, and TNF secretions from (B). **p < 0.01 by ANOVA.
(D) Flow cytometry analysis showswild-type BMDMs stainedwith themitochondrial superoxide-specific stainMitoSOX and then left unstimulated, or treatedwith
2DG for 2 hr before incubation with ATP (2 mM) for 30 min after LPS stimulation. **p < 0.01 by ANOVA.
(E) Immunoblot analysis for caspase-1 of cell lysates from wild-type BMDMs pre-treated with glucose-free media for 2 hr, followed by the addition of increasing
concentrations of glucose (0, 5.0, and 22.5 mM) before stimulation with LPS and ATP. b-actin served as the standard.
(F) Luminex assay and ELISA assay for IL-1b, IL-18, and TNF secretions in supernatants from (E) are shown. **p < 0.01 by ANOVA.
See also Figures S4 and S5.macrophages pre-treated with 2DG (0.5 mM) for 2 hr before LPS
and ATP stimulation. 2DG significantly suppressed the increase
of ECAR in response to LPS and ATP compared to vehicle
control (Figure 6A).Next, to investigate the effect of glycolysis inhibition by 2DG
on NLRP3 inflammasome activation, we analyzed caspase-1
activation in LPS-primed BMDMs pre-treated with 2DG
(0.5 mM) for 2 hr before ATP treatment. Consistent with theCell Reports 12, 102–115, July 7, 2015 ª2015 The Authors 109
results obtainedwith Torin1, 2DG inhibited caspase-1 activation,
while NLRP3 and ASC expressions were unchanged (Figure 6B).
Moreover, the secretions of IL-1b and IL-18 were decreased by
2DG treatment, while TNF was unchanged (Figure 6C). Since we
have reported previously that mitochondrial reactive oxygen
species (mtROS) are required for NLRP3-dependent caspase-1
activation (Nakahira et al., 2011), we analyzed the effect of 2DG
on mtROS generation. 2DG treatment significantly suppressed
mtROS generation in response to LPS and ATP compared to
control (Figure 6D).
We investigated whether the effects of 2DG related to glycol-
ysis inhibition could involve regulation of the energy-sensing
kinase AMPK. Treatment with 2DG had no effect on the activa-
tion of AMPK at the doses of 2DG tested, whereas 2DG inhibited
caspase-1 activation (Figures S4A and S4B). Consistently, 2DG
did not significantly affect translational activation through the
phosphorylations of p70S6K, S6, and 4E-BP1 (Figure S4A).
Moreover, AICAR, an activator of AMPK, did not affect cas-
pase-1 activation and secretions of IL-1b and IL-18 in wild-
type BMDMs in response to LPS and ATP compared to control,
as previously reported (Wen et al., 2011; Figure S4C). These re-
sults suggest that AMPK was not involved in the suppression of
caspase-1 activation by inhibition of glycolysis.
We also examined the requirement for glycolysis in NLRP3 in-
flammasome activation by using deprivation of glucose to inhibit
glycolysis (Greiner et al., 1994). Similar to the effects of 2DG,
glucose deprivation inhibited caspase-1 activation and secre-
tions of IL-1b and IL-18 in wild-type BMDMs in response to
LPS and ATP, while TNF secretion was unchanged (Figures 6E
and 6F). Importantly, the inhibitory effects of glucose deprivation
on caspase-1 activation and secretions of IL-1b and IL-18 were
dose-dependently reversed by increasing the concentration of
glucose in the media, while TNF was unchanged (Figures 6E
and 6F). Consistent with the results observed in BMDMs, niger-
icin-induced secretions of IL-1b and IL-18 in human THP-1 mac-
rophages were inhibited by 2DG (Figure S5A). In contrast, 2DG
did not significantly affect the secretions of IL-1b and IL-18 in
wild-type BMDMs subjected to LPS and poly(dA:dT) treatment,
which activates the AIM2 inflammasome pathway (Figure S5B).
These results suggest that mTORC1-dependent glycolysis is a
critical metabolic pathway involved in NLRP3 inflammasome
activation.
HK1-Dependent Glycolysis Is Required for NLRP3
Inflammasome Activation
To analyze whether HK1 can play a critical role in NLRP3 inflam-
masome activation, we investigated the effect of HK1 deficiency
on NLRP3 inflammasome activation. Genetic deletion of HK1 re-
sults in early embryonic lethality in mice, precluding the use of
Hk1/ mice in the current study (Fueger et al., 2003). Hence,
we used two independent shRNAs to downregulate HK1 expres-
sion in wild-type peritoneal macrophages. The activation of cas-
pase-1 in response to LPS and ATP stimulation was suppressed
by HK1 shRNA transduction relative to control shRNA transduc-
tion, while NLRP3 and ASC expressions were unchanged
(Figure 7A). Moreover, the secretions of IL-1b and IL-18 were
inhibited by HK1 shRNA in peritoneal macrophages, while
TNF was unchanged (Figure 7B). Consistent with the results110 Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authorsobserved with 2DG treatment, HK1 knockdown by HK1 shRNA
suppressed the production of glycolytic metabolites (i.e.,
glucose-6-phosphate, citrate, and lactate) in peritoneal macro-
phages in response to LPS and ATP, compared to control
shRNA-transduced cells (Figure 7C).
Similarly, increased glucose uptake and the PEP, citrate, and
lactate productions induced by LPS and ATP were significantly
suppressed by HK1 knockdown, using HK1 siRNA in mouse
J774A.1 macrophages prior to stimulation with LPS and ATP
(Figure S6A). Knockdown of HK1 using HK1-specific siRNA in-
hibited the activation of caspase-1 in mouse J774A.1 macro-
phages in response to LPS and ATP, compared to control
siRNA-transfected cells (Figure S6B). Moreover, knockdown of
HK1 inhibited the secretions of IL-1b and IL-18 in response to
LPS and ATP relative to control siRNA-transfected cells, while
TNF was unchanged (Figure S6C). Consistent with the results
observed with 2DG treatment, knockdown of HK1 by transduc-
tion with HK1 siRNA inhibited mtROS generation in response to
LPS and ATP, compared to control siRNA-transfected cells
(Figure S6D).
Next, we sought to investigate whether overexpression of HK1
could rescue the effect of mTORC1 inhibition on NLRP3 inflam-
masome activation. We overexpressed HK1 in mouse J774A.1
macrophages and validated the expression levels by western
immunoblot analysis (Figure 7D). The mTORC1 inhibition by
Torin1 suppressed caspase-1 activation and secretions of
IL-1b and IL-18 in response to LPS and ATP stimulation, relative
to control (Figures 7D and 7E). Importantly, the inhibitory effects
of Torin1 treatment on caspase-1 activation and secretions of
IL-1b and IL-18 were reversed by overexpression of HK1, while
TNF was unchanged (Figures 7D and 7E).
To evaluate whether glycolysis activation can serve as an up-
stream mechanism for NLRP3-mediated caspase-1 activation,
we analyzed caspase-1 activation and glycolysis activation
represented by the production of glycolytic metabolites (i.e.,
glucose-6-phosphate, citrate, and lactate) in wild-type BMDMs
pre-treated with Z-VAD, a selective caspase-1 inhibitor, for
1 hr before LPS and ATP stimulation. Z-VAD suppressed cas-
pase-1 activation and secretions of IL-1b and IL-18 in response
to LPS and ATP stimulation relative to vehicle control, while TNF
was unchanged (Figures S7A and S7B). In contrast, Z-VAD did
not change the production of glycolytic metabolites (i.e.,
glucose-6-phosphate, citrate, and lactate) by LPS and ATP stim-
ulation relative to vehicle control (Figure S7C). These results
suggest that HK1-dependent glycolysis is required for NLRP3
inflammasome activation.
DISCUSSION
In this paper, we show that mTORC1-induced glycolysis pro-
vides a critical mechanism for NLRP3 inflammasome activation
in macrophages. We also demonstrate that HK1-dependent
glycolysis, under the regulation of mTORC1, represents a crucial
metabolic pathway that is required for NLRP3 inflammasome
activation. Furthermore, we show that activation of the glycolytic
phenotype is linked to the immune response.
Among the family of NLRs, the NLRP3 inflammasome is
unique in its ability to recognize molecular patterns associated
Figure 7. Deficiency of HK1-Dependent Glycolysis Suppresses NLRP3 Inflammasome Activation
(A) Immunoblot analysis for HK1, caspase-1, and IL-1b in cell lysates from wild-type mice peritoneal macrophages transduced with lentiviruses expressing
non-target shRNA (control shRNA) or two independent shRNAs for HK1 (shHK1 1 and 2) and stimulated with LPS and ATP. b-actin served as the standard.
(B) ELISA assays show IL-1b, IL-18, and TNF secretions from (A). **p < 0.01 by ANOVA.
(C) Glucose-6-phosphate, citrate, and lactate production assays from wild-type peritoneal macrophages transduced with lentiviruses expressing non-target
shRNA (control shRNA) or two independent shRNAs for HK1 (shHK1 1 and 2) and stimulated with LPS and ATP are shown. *p < 0.05 by ANOVA.
(D) Immunoblot analysis for Myc-tagged HK1, caspase-1, and IL-1b of cell lysates from mouse J774A.1 macrophages transfected with control vector or
Myc-tagged Hk1 expression vector, treated with LPS (500 ng/ml) for 4 hr, and followed by incubation with ATP (5 mM) for 30 min. b-actin served as the standard.
(E) ELISA assays show IL-1b, IL-18, and TNF secretions from (D). *p < 0.05 by ANOVA.
See also Figures S6 and S7.with host-derivedmetabolites, such as glucose or saturated fatty
acids (Jourdan et al., 2013; Tannahill et al., 2013; Zhou et al.,
2010). Although recent reports indicate that the NLRP3 inflam-
masome is regulated by metabolic changes in association withhigh-fat diet-induced obesity (Stienstra et al., 2011; Vandanmag-
sar et al., 2011), it has remained unclear whether cellular glycol-
ysis can regulate NLRP3 inflammasome activation. Here we
have demonstrated that mTORC1-HK1-dependent glycolysisCell Reports 12, 102–115, July 7, 2015 ª2015 The Authors 111
was required for NLRP3 inflammasome activation in response to
pro-inflammatory stimuli. Genetic and pharmacologic downre-
gulation of Raptor/mTORC1 or HK1 inhibited the activation of
glycolysis and NLRP3 inflammasome-mediated caspase-1 acti-
vation in macrophages. The inhibition of the mTOR pathway by
downregulation of Raptor/mTORC1 affected the regulation of
both pro-IL-1b maturation and caspase-1 activation during
NLRP3 inflammasome activation. Consistently, we also have
shown that glucose deprivation markedly suppressed NLRP3 in-
flammasome-mediated caspase-1 activation in response to LPS
and ATP. In contrast, we have shown that the inhibition of glycol-
ysis by 2DG did not affect AIM2 inflammasome activation. Simi-
larly, we have demonstrated that activation of HK1-dependent
glycolysis was not involved in AIM2 inflammasome activation.
Collectively, our results suggest that the activation of glycolysis
is required for NLRP3 inflammasome activation.
Glycolysis is a critical pathway in cellular glucose metabolism
that provides intermediates for energy generation. The increased
expression and activity of HK is critical for persistent consump-
tion of glucose-6-phosphate by the glycolytic pathway in order
to attain a high glycolytic phenotype (Azoulay-Zohar and Aflalo,
1999, 2000; Baijal and Wilson, 1995; Crane and Sols, 1953; Ma-
thupala et al., 2009; Parry and Pedersen, 1984; Wilson, 2003).
Anaerobic glycolysis is an effective means of energy production
during short intense exercise, providing energy for short periods
ranging from 10 s to 2 min. The speed at which ATP is produced
is about 100 times that of oxidative phosphorylation (OXPHOS)
(Koppenol and Bounds, 2009; Vander Heiden et al., 2009).
Recently, HK2 also has been shown to be responsible for TLR-
driven high glycolytic rates in dendritic cells (Everts et al.,
2014). In contrast, we found that HK1 is the major isoform of
HK expressed in BMDMs, whereas HK2 is not expressed in
these cells. In LPS-primed macrophages, glucose utilization
and glycolytic metabolites were rapidly increased via increased
HK1 protein expression as early as 30 min after ATP treatment.
The rapid increase in HK1 protein levels may explain, in part,
how glucose uptake and glycolytic metabolites were markedly
increased with short kinetics. We suggest that the high glycolytic
phenotype observed during NLRP3 inflammasome activation is
regulated by the rapid increase of HK1 protein in macrophages.
Among four HK isozymes (HK1–4), HK1 is ubiquitously ex-
pressed in all mammalian tissues (Azoulay-Zohar and Aflalo,
1999, 2000; Baijal and Wilson, 1995; Crane and Sols, 1953; Ma-
thupala et al., 2009; Parry and Pedersen, 1984; Wilson, 2003).
However, the mechanism by which HK1 expression is regulated
remains poorly understood. In our study, we found that the pro-
tein expression of HK1 was regulated by mTORC1-dependent
translation in response to LPS and ATP in macrophages. The in-
hibition of translation by Torin1 or Raptor/mTORC1 knockdown
suppressed HK1 protein levels. Consistently, the activation of
translation by knockdown of the inhibitory protein 4E-BP1
increased HK1 protein levels. The initiation of translation by
mTORC1 is regulated through the phosphorylation state of
eIFs and other factors (Richter and Sonenberg, 2005). The
eIF4E activity is tightly regulated by reversible interaction with
4E-BP (Richter and Sonenberg, 2005). Among three known 4E-
BPs (4E-BP1, 4E-BP2, and 4E-BP3), 4E-BP1 specifically plays
a major role in translation by inhibiting cap-dependent transla-112 Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authorstion initiation through the regulation of eIF4E phosphorylation
(Richter and Sonenberg, 2005). Previous studies have demon-
strated a critical role of 4E-BP1 in adipogenesis and metabolism
in mammals, such that 4ebp1/ mice displayed increased
metabolic rate. Furthermore, deficiency of 4E-BP1 increased
the protein levels of the mitochondrial biogenesis factor peroxi-
some proliferator-activated receptor-g co-activator 1 (PGC1)
via stimulating translation, whereas the mRNA levels of this fac-
tor were unaffected (Tsukiyama-Kohara et al., 2001). According
to our data, we suggest that HK1 protein expression was
regulated by mTORC1-dependent translation via 4E-BP1 in
macrophages.
Several proteins that have a metabolic function, such as thio-
redoxin-interacting protein (TXNIP), VDACs, and mitochondrial
antiviral signaling proteins (MAVs), have been associated with
NLRP3 inflammasome activation (Subramanian et al., 2013;
Zhou et al., 2010, 2011). While the protein expression of HK1
was not induced in response to AIM2 inflammasome activation,
the expression of HK1 was selectively increased during NLRP3
inflammasome activation. A considerable variation in the propor-
tion of HK activity bound to the mitochondria occurs in different
cell types and tissues, with the majority found in the bound form
in tissues, such as brain and kidney, where HK1 is highly ex-
pressed (Azoulay-Zohar and Aflalo, 1999, 2000; Baijal and Wil-
son, 1995; Crane and Sols, 1953; Mathupala et al., 2009; Parry
and Pedersen, 1984; Wilson, 2003). Consistent with previous
results, we have shown that HK1 expression was found mainly
in the mitochondrial fraction of macrophages. HK1 exhibited a
higher affinity for the VDAC1 isoform than for other mammalian
VDAC isoforms (Azoulay-Zohar and Aflalo, 1999, 2000). Given
that VDAC is essential for NLRP3 inflammasome activation
(Zhou et al., 2011), it is likely that the interaction of HK1 with
VDAC1 in mitochondria can confer specific functional advan-
tages for NLRP3 inflammasome activation. In our study, we
demonstrated the interaction of HK1 with VDAC1 in the mito-
chondria of macrophages. We suggest that mitochondrial inter-
action of HK1 and VDAC1may represent another factor essential
for NLRP3 inflammasome activation in macrophages.
In conclusion, we found that mTORC1-HK1-dependent glycol-
ysis regulates NLRP3 inflammasome activation in macrophages.
Wealso determined that the activation of the glycolytic phenotype
is linked to the immune response. Given the complex relationship
between the NLRP3 inflammasome and cellular glycolysis, our
findings may have broad implications for therapeutic targeting in
human diseases, not only limited to metabolic diseases but also
diseases in which inflammation plays a key role.EXPERIMENTAL PROCEDURES
Mice
Mice were genotyped with standard PCR of tail DNA. All animal experimental
protocols were approved by the Harvard Standing Committee for Animal Wel-
fare (protocol 04435, Harvard Medical School) and the Institutional Animal
Care and Use Committee (protocol 2013-0108, Weill Cornell Medical College).
Reagents and Antibodies
LPS (Escherichia coli) (tlrl-pelps), MDP (tlrl-mdp), and flagellin (Salmonella
typhimurium) (tlrl-stfla) were from InvivoGen. ATP (A2383), nigericin (N7143),
2DG (D3875), AICAR (A9978), andpoly(dA:dT) (P0883)were fromSigma-Aldrich.
Torin1 (4247) and Z-VAD-FMK (2163) were from Tocris Bioscience. Rapamycin
(9904) was from Cell Signaling Technology. The following antibodies were
used: polyclonal rabbit anti-caspase-1 for mouse caspase-1 (SC-514, Santa
Cruz Biotechnology); polyclonal goat anti-IL-1b for mouse IL-1b (AF-401-NA,
R&D Systems); monoclonal mouse anti-NLRP3 for mouse NLRP3 (ALX-804-
881-C100, Enzo Life Sciences); polyclonal rabbit anti-ASC for mouse ASC
(AP07815PU-N, Acris Antibodies); glycolysis antibody sampler kit for anti-HK1
and anti-glycolytic enzymes (8337, Cell Signaling Technology); translational
control antibody sampler kit for phospho-eIF4E, phospho-p70 S6 kinase, phos-
pho-S6, and phospho-4E-BP1 (9918, Cell Signaling Technology); AMPK and
ACC antibody sampler kit for phospho-AMPKa, AMPKa, phospho-ACC, and
ACC (9957, Cell Signaling Technology); monoclonal rabbit anti-Raptor (2280,
Cell Signaling Technology); monoclonal rabbit anti-Rictor (9476, Cell Signaling
Technology); monoclonal rabbit anti-mTOR (2983, Cell Signaling Technology);
monoclonal rabbit anti-4E-BP1 (9644, Cell Signaling Technology); monoclonal
rabbit anti-Myc-Tag (2278, Cell Signaling Technology); and monoclonal mouse
anti-b-actin (A5316, Sigma-Aldrich).
Cell Culture
BMDMs were prepared as described previously (Sutterwala et al., 2006).
Bone marrow collected from mouse femurs and tibias was plated on sterile
petri dishes and incubated for 7 days in DMEM (Invitrogen) containing 10%
(v/v) heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin,
100 mg/ml streptomycin, and 25% (v/v) conditioned medium from mouse
L929 fibroblasts (CCL-1, ATCC). Cells were incubated for 4 hr with LPS
(500 ng/ml) and then were treated with ATP (2 mM) for 30 min as described.
Mice were injected with thioglycollate broth medium (1.0 ml, i.p.). After
4 days, peritoneal cells were collected from mice with cold PBS. Cells were
incubated for 2 hr with DMEM containing 10% (v/v) heat-inactivated FBS,
penicillin, and streptomycin in six-well tissue culture plates. Non-adherent
cells were removed by gently washing with PBS. After cells were cultured
overnight, cells were incubated for 4 hr with LPS (500 ng/ml) and then were
treated with ATP (5 mM) for 30 min as described. Mouse J774A.1 macro-
phages (TIB-67, ATCC) were cultured in DMEM containing 10% (v/v) FBS,
penicillin, and streptomycin. Human THP-1 monocyte-derived macrophages
(TIB-202, ATCC) were grown in RPMI-1640 media (Invitrogen) containing 10%
(v/v) FBS, penicillin, and streptomycin. THP-1 cells were differentiated for
16 hr with 50 nM phorbol 12-myristate-13-acetate. Cells were incubated for
6 hr with nigericin (6.7 mM).
Immunoblot Analysis
Cells or tissues were harvested, lysed in 23 SDS loading buffer or NP40 Cell
Lysis Buffer (FNN0021, Invitrogen), and then briefly sonicated. Lysates were
centrifuged at 15,300 3 g for 10 min at 4C, and the supernatants were ob-
tained. The protein concentrations of the supernatants were determined using
the Bradford assay (Bio-Rad). Proteins were electrophoresed on NuPAGE
4%–12% Bis-Tris gels (Invitrogen) and transferred to Protran nitrocellulose
membranes (10600001, GE Healthcare).
Cytokine Analysis
Cell culture supernatants or serum was measured for mouse and human IL-1b
and IL-18 using ELISA (R&D Systems) and Luminex multiplex cytokine assays,
according to the manufacturer’s instructions. Cell culture supernatants or
serum was measured for mouse TNF using ELISA (R&D Systems).
qRT-PCR
Total RNA was isolated from cultured cells and tissues using the TRIzol re-
agent (15596-018, Invitrogen), according to the manufacturer’s instructions.
For qRT-PCR, cDNA was synthesized from 4 mg total RNA using random
hexamers and SuperScript Reverse Transcriptase II (18064-014, Invitrogen),
according to the manufacturer’s instructions. A 10-ml mixture containing the
diluted cDNA and a set of gene-specific primers was mixed with 10 ml 23
SYBR Green PCR Master Mix (4309155, Applied Biosystems) and then
subjected to RT-PCR quantification using the ABI PRISM 7500 real-time
PCR system (Applied Biosystems). The following primers were used: mouse
Hk1 forward, 50-TGCCATGCGGCTCTCTGATG-30 and reverse, 50- CTTGACGGAGGCCGTTGGGTT-30; mouse Gapdh forward, 50-GGTGAAGGTCGGTGT
GAACGGA-30 and reverse, 50-CCAAAGTTGTCATGGATGACCTTGG-30.
Transduction of shRNA and Transfection of siRNA
For stable knockdown of mouse Raptor, two independent shRNAs
(TRCN0000077469andTRCN0000077471, Sigma-Aldrich)were used. For sta-
ble knockdown ofmouseRictor, two independent shRNAs (TRCN0000123394
and TRCN0000123395, Sigma-Aldrich) were used. For stable knock-
down of mouse Hk1, two independent shRNAs (TRCN0000297076 and
TRCN0000278141,Sigma-Aldrich)were used. For stable knockdownofmouse
4e-bp1, two independent shRNAs (TRCN0000335449 and TRCN0000335450,
Sigma-Aldrich) were used.
Mouse peritoneal macrophages (5 3 105 cells/well) were seeded in six-well
plates and were transduced with shRNA lentiviral constructs against mouse
Raptor, Rictor, Hk1, or non-target shRNA (SHC016, Sigma-Aldrich) for control.
For transient knockdown of mousemTOR,Hk1, and 4e-bp1, siRNAs ofmTOR
(EMU047451), Hk1 (EMU086531), and 4e-bp1 (EMU029571) were obtained
from Sigma-Aldrich. Mouse J774A.1 macrophages (2 3 105 cells/well) were
seeded in six-well plates and were transfected with siRNAs for mouse
mTOR, Hk1, 4e-bp1, or siRNA Universal Negative Control (SIC001, Sigma-
Aldrich) (200 ng/well) using Lipofectamin RNAiMAX reagent (13778-075, Invi-
trogen), according to the manufacturer’s instructions. For overexpression of
HK1, mouse Hk1 cDNA ORF clone (Myc-DDK tagged) (MR204388, OriGene)
was used. Mouse J774A.1 macrophages (2 3 105 cells/well) were seeded in
six-well plates and were transfected with Hk1 cDNA ORF clone or control vec-
tor using Lipofectamine LTX Reagent with Plus reagent (15338-100, Invitro-
gen), according to the manufacturer’s instructions. For AIM2 inflammasome
activation, LPS-primed wild-type BMDMs were transfected with poly(dA:dT)
(1 mg/ml) (Sigma-Aldrich) using Lipofectamine with Plus reagent (15338-100,
Invitrogen), according to the manufacturer’s instructions.
mtROS Production Assay
mtROS were measured by MitoSOX (M36008, Invitrogen) staining. Cells were
incubated with MitoSOX (5 mM) for 15 min at 37C. Cells were washed with
PBS, treated with trypsin, and resuspended in PBS containing 1% (v/v)
heat-inactivated FBS. Data were acquired with a FACSCanto II (BD Biosci-
ences) and were analyzed with FlowJo analytical software (Tree Star).
Glycolytic Function Assay
For the glycolytic function assay, peritoneal cells (5 3 104 cells/well) were
plated on XF96 cell culture microplates (101085-004, Seahorse Bioscience).
ECAR or OCR, as parameters of glycolytic flux, was measured on a Seahorse
XF96 bioanalyzer, using the XF Glycolysis Stress Test kit according to the
manufacturer’s instructions (102194-100, Seahorse Bioscience).
Glucose Uptake, Glucose-6-Phosphate, PEP, Citrate, and Lactate
Production Assays
For the glucose uptake assay, cells (53 105 cells/well) were plated on six-well
plates. Cells were then incubated in a glucose-free DMEM (Invitrogen) for 1 hr.
After the addition of 18F-FDG (0.3 MBq), the cells were incubated at 37C for
30 min. The cells were washed twice with PBS. Cells were harvested in PBS
for radioactivity measurement using a 1480 Wizard 3 g-counter (PerkinElmer).
Data shown are the mean ± SD of triplicate samples from a representative
experiment. The PEP production was measured using a PEP fluorometric
assay kit, according to the manufacturer’s instructions (700780, Cayman
Chemical). The glucose-6-phosphate (657-100, BioVision Technologies), cit-
rate (K655-100, BioVision Technologies), and lactate (K607-100, BioVision
Technologies) productions were measured using colorimetric assay methods,
according to the manufacturer’s instructions.
Statistical Analysis
All data are mean ± SD, combined from three independent experiments. All
statistical tests were analyzed by Student’s two-tailed t test for comparison
of two groups and ANOVA (with post hoc comparisons using Dunnett’s test)
with a statistical software package (GraphPad Prism version 4.0) for compar-
ison of multiple groups. p values of less than 0.05 were considered statistically
significant. Survival was analyzed with the log-rank test.Cell Reports 12, 102–115, July 7, 2015 ª2015 The Authors 113
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